Ectopic fat: the true culprit linking obesity and cardiovascular disease?

Summary

Obesity is a major risk factor for cardiovascular disease and its complications. However, not all fat depots share the same characteristics. Recent studies have found that ectopic rather than subcutaneous fat accumulation is associated with increased cardiometabolic risk. However, ectopic fat accumulation can be seen initially as a protective mechanism against lipotoxicity. Subsequently the adipose tissue becomes dysfunctional, thus inducing systemic metabolic alterations (through release of cytokines) or specific organ dysfunctions. The purpose of this review is to summarise the current available data on the impact of excess adiposity vs ectopic fat in the development of cardiometabolic diseases.

• References

• 1 Abbasi F. et al. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002; 40: 937-943.
• 2 Zalesin KC. et al. Impact of obesity on cardiovascular disease. Endocrinol Metab Clin North Am 2008; 37: 663-684. ix
• 3 Li TY. et al. Obesity as compared with physical activity in predicting risk of coronary heart disease in women. Circulation 2006; 113: 499-506.
• 4 Strazzullo P. et al. Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke 2010; 41: e418-e426.
• 5 Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998; 97: 2099-2100.
• 6 Gopalan C. Rising incidence of obesity, coronary heart disease and diabetes in the Indian urban middle class. Possible role of genetic and environmental factors. World Rev Nutr Diet 2001; 90: 127-143.
• 7 Stehbens WE. The epidemiological relationship of hypercholesterolemia, hypertension, diabetes mellitus and obesity to coronary heart disease and atherogenesis. J Clin Epidemiol 1990; 43: 733-741.
• 8 DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010; 53: 1270-1287.
• 9 Gastaldelli A, Basta G. Ectopic fat and cardiovascular disease: what is the link?. Nutr Metabol Cardiovasc Dis 2010; 20: 481-490.
• 10 Sironi AM. et al. Impact of increased visceral and cardiac fat on cardiometabolic risk and disease. Diabetic Med 2012; 29: 622-627.
• 11 Sacks HS, Fain JN. Human epicardial fat: what is new and what is missing?. Clin Exp Pharmacol Physiol 2011; 38: 879-887.
• 12 Snel M. et al. Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int J Endocrinol 2012; 2012: 983814.
• 13 Pischon T. et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359: 2105-2120.
• 14 Manson JE. et al. Body weight and mortality among women. N Engl J Med 1995; 333: 677-685.
• 15 Bacha F. et al. Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors. J Clin Endocrinol Metab 2003; 88: 2534-2540.
• 16 Cartier A. et al. Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-alpha in men. J Clin Endocrinol Metab 2008; 93: 1931-1938.
• 17 Cote M. et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 2005; 90: 1434-1439.
• 18 Boyko EJ. et al. Visceral adiposity, fasting plasma insulin, and lipid and lipoprotein levels in Japanese Americans. Int J Obes Relat Metab Disord 1996; 20: 801-808.
• 19 Nieves DJ. et al. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes 2003; 52: 172-179.
• 20 Fox CS. et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39-48.
• 21 Banerji MA. et al. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999; 84: 137-44.
• 22 Tchernof A. et al. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 1996; 19: 629-637.
• 23 Pascot A. et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001; 42: 2007-2014.
• 24 Larsson B. et al. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J 1984; 288: 1401-1404.
• 25 Ohlson LO. et al. The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 1985; 34: 1055-1058.
• 26 Yusuf S. et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-1649.
• 27 Brunzell JD, Fujimoto WY. Body fat distribution and dyslipidemia. Am J Med 1995; 99: 457-458.
• 28 Matsuzawa Y. et al. Pathophysiology and pathogenesis of visceral fat obesity. Obes Res 1995; 3 (Suppl. 02) 187S-194S.
• 29 Despres JP. et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008; 28: 1039-1049.
• 30 Ross R, Despres JP. Abdominal obesity, insulin resistance, and the metabolic syndrome: contribution of physical activity/exercise. Obesity 2009; 17 (Suppl. 01) S1-S2.
• 31 Enzi G. et al. Historical perspective: visceral obesity and related comorbidity in Joannes Baptista Morgagni’s ’De sedibus et causis morborum per anatomen indagata’. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 2003; 27: 534-535.
• 32 Vague J. Sexual differentiation, a factor affecting the forms of obesity. Presse Med 1947; 55: 339.
• 33 Cornier MA. et al. Assessing adiposity: a scientific statement from the American Heart Association. Circulation 2011; 124: 1996-2019.
• 34 Bluher M. Are there still healthy obese patients?. Curr Opin Endocrinol Diabetes Obes 2012; 19: 341-346.
• 35 Lee K. Metabolically obese but normal weight (MONW) and metabolically healthy but obese (MHO) phenotypes in Koreans: characteristics and health behaviors. Asia Pac J Clin Nutr 2009; 18: 280-284.
• 36 Karelis AD. et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab 2005; 90: 4145-4150.
• 37 Kantartzis K. et al. Effects of a lifestyle intervention in metabolically benign and malign obesity. Diabetologia 2011; 54: 864-868.
• 38 Pataky Z. et al. Metabolic normality in overweight and obese subjects. Which parameters? Which risks?. Int J Obes 2011; 35: 1208-1215.
• 39 Calori G. et al. Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. Diabetes Care 2011; 34: 210-215.
• 40 Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab 2012; 97: 2482-2488.
• 41 Muscelli E. et al. Influence of duration of obesity on the insulin resistance of obese non-diabetic patients. Int J Obes Relat Metab Disord 1998; 22: 262-267.
• 42 Ruderman NB. et al. The "metabolically-obese," normal-weight individual. Am J Clin Nutr 1981; 34: 1617-1621.
• 43 Pou KM. et al. Patterns of abdominal fat distribution: the Framingham Heart Study. Diabetes Care 2009; 32: 481-485.
• 44 Bugianesi E. et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48: 634-642.
• 45 Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012; 33: 981-1030.
• 46 Ruderman NB. et al. Obesity-associated disorders in normal-weight individuals: some speculations. Int J Obes 1982; 6 (Suppl. 01) 151-157.
• 47 Carnethon MR. et al. Association of weight status with mortality in adults with incident diabetes. J Am Med Assoc 2012; 308: 581-590.
• 48 Bluher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 2009; 117: 241-250.
• 49 Kirtland J, Gurr MI. Adipose tissue cellularity: a review. 2. The relationship between cellularity and obesity. Int J Obes 1979; 3: 15-55.
• 50 Bjorntorp P. et al. Adipose tissue fat cell size and number in relation to metabolism in randomly selected middle-aged men and women. Metabolism 1971; 20: 927-935.
• 51 Bjorntorp P. Sjostrom L,+SJOSTROM L: Number and size of adipose tissue fat cells in relation to metabolism in human obesity. Metabolism 1971; 20: 703-713.
• 52 Jernas M. et al. Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expression. Faseb J 2006; 20: 1540-1542.
• 53 Krotkiewski M. et al. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest 1983; 72: 1150-1162.
• 54 Hammarstedt A. et al. Adipose tissue dysregulation and reduced insulin sensitivity in non-obese individuals with enlarged abdominal adipose cells. Diabetol Metab Syndr 2012; 4: 42.
• 55 Alligier M. et al. Subcutaneous adipose tissue remodeling during the initial phase of weight gain induced by overfeeding in humans. J Clin Endocrinol Metabol 2012; 97: E183-E192.
• 56 Bays H. et al. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metabol 2004; 89: 463-478.
• 57 Hotamisligil GS. et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415.
• 58 Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112: 1785-1788.
• 59 Kim JY. et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 2007; 117: 2621-2637.
• 60 Alessi MC. et al. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol 2007; 18: 240-245.
• 61 Verrijken A. et al. Prothrombotic factors in histologically proven NAFLD and NASH. Hepatology. 2013. Epub ahead of print.
• 62 Bugianesi E, Gastaldelli A. Hepatic and cardiac steatosis: are they coupled?. Heart Fail Clin 2012; 8: 663-670.
• 63 Despres JP. Excess visceral adipose tissue/ectopic fat the missing link in the obesity paradox?. J Am Coll Cardiol 2011; 57: 1887-1889.
• 64 Snel M. et al. Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int J Endocrinol 2012; 2012: 983814.
• 65 Sironi AM. et al. Impact of increased visceral and cardiac fat on cardiometabolic risk and disease. Diabet Med 2012; 29: 622-627.
• 66 Gastaldelli A. et al. The role of cardiac fat in insulin resistance. Curr Opin Clin Nutr Metab Care 2012; 15: 523-528.
• 67 Ahn SG. et al. Relationship of epicardial adipose tissue by echocardiography to coronary artery disease. Heart 2008; 94: e7.
• 68 Greif M. et al. Pericardial adipose tissue determined by dual source CT is a risk factor for coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29: 781-786.
• 69 Jeong JW. et al. Echocardiographic epicardial fat thickness and coronary artery disease. Circ J 2007; 71: 536-539.
• 70 Rosito GA. et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation 2008; 117: 605-613.
• 71 Mahabadi AA. et al. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J 2009; 30: 850-856.
• 72 Mazurek T. et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003; 108: 2460-2466.
• 73 Perseghin G. et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008; 47: 51-58.
• 74 Iacobellis G, Leonetti F. Epicardial adipose tissue and insulin resistance in obese subjects. J Clin Endocrinol Metab 2005; 90: 6300-6302.
• 75 Wang CP. et al. Increased epicardial adipose tissue (EAT) volume in type 2 diabetes mellitus and association with metabolic syndrome and severity of coronary atherosclerosis. Clin Endocrinol 2009; 70: 876-882.
• 76 Wang TD. et al. Relations of epicardial adipose tissue measured by multidetector computed tomography to components of the metabolic syndrome are region-specific and independent of anthropometric indexes and intraabdominal visceral fat. J Clin Endocrinol Metab 2009; 94: 662-669.
• 77 Marchington JM. et al. Adipose tissue in the mammalian heart and pericardium: structure, foetal development and biochemical properties. Comp Biochem Physiol B 1989; 94: 225-232.
• 78 Marchington JM, Pond CM. Site-specific properties of pericardial and epicardial adipose tissue: the effects of insulin and high-fat feeding on lipogenesis and the incorporation of fatty acids in vitro. Int J Obes 1990; 14: 1013-1022.
• 79 Iozzo P. et al. Contribution of glucose tolerance and gender to cardiac adiposity. J Clin Endocrinol Metab 2009; 94: 4472-4482.
• 80 McGavock JM. et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007; 116: 1170-1175.
• 81 Rijzewijk LJ. et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008; 52: 1793-1799.
• 82 Zhou YT. et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000; 97: 1784-1789.
• 83 Christoffersen C. et al. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology 2003; 144: 3483-3490.
• 84 Targher G. et al. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. New Engl J Med 2010; 363: 1341-1350.
• 85 Sung KC. et al. Fatty Liver, Insulin Resistance, and Features of Metabolic Syndrome: Relationships with coronary artery calcium in 10,153 people. Diabetes Care. 2012. Epub ahead of print.
• 86 Gastaldelli A. et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009; 49: 1537-1544.
• 87 Mofrad P. et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-1292.
• 88 Ricci C. et al. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 1997; 27: 108-113.
• 89 Fabbrini E. et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008; 134: 424-431.
• 90 Yki-Jarvinen H. Fat in the liver and insulin resistance. Ann Med 2005; 37: 347-356.
• 91 Gastaldelli A. et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007; 133: 496-506.
• 92 Targher G. et al. Risk of all-cause and cardiovascular mortality in patients with chronic liver disease. Gut 2011; 60: 1602-1603. author reply 1603-1604.
• 93 Bhatia LS. et al. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur Heart J 2012; 33: 1190-1200.
• 94 Villanova N. et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005; 42: 473-480.
• 95 Kozakova M. et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology 2012; 55: 1406-1415.
• 96 Bonapace S. et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 2012; 35: 389-395.
• 97 Bjorntorp P. Visceral obesity: a "civilisation syndrome". Obes Res 1993; 1: 206-222.
• 98 Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care 1999; 22 (Suppl. 01) C10-C13.
• 99 Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994; 74: 761-811.
• 100 Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93 (11) (Suppl. 01) S57-S63.
• 101 Mathieu P. et al. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009; 53: 577-584.
• 102 Matsuzawa Y. The role of fat topology in the risk of disease. Int J Obes 2008; 32 (Suppl. 07) S83-S92.
• 103 Bastelica D. et al. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 2002; 22: 173-178.
• 104 Mertens I, Van Gaal LF. Visceral fat as a determinant of fibrinolysis and hemostasis. Semin Vasc Med 2005; 5: 48-55.
• 105 Van Gaal LF. et al. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875-880.
• 106 Sironi AM. et al. Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension 2004; 44: 127-133.
• 107 Sam S. et al. Relationship of abdominal visceral and subcutaneous adipose tissue with lipoprotein particle number and size in type 2 diabetes. Diabetes 2008; 57: 2022-2027.
• 108 Sam S. et al. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care 2009; 32: 932-937.
• 109 Liu J. et al. Fatty liver, abdominal visceral fat, and cardiometabolic risk factors: the Jackson Heart Study. Arterioscler Thromb Vasc Biol 2011; 31: 2715-2722.
• 110 Liu J. et al. Impact of abdominal visceral and subcutaneous adipose tissue on cardiometabolic risk factors: the Jackson Heart Study. J Clin Endocrinol Metab 2010; 95: 5419-5426.
• 111 Tadros TM. et al. Pericardial fat volume correlates with inflammatory markers: the Framingham Heart Study. Obesity 2010; 18: 1039-1045.
• 112 Preis SR. et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity 2010; 18: 2191-2198.
• 113 Pou KM. et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 2007; 116: 1234-1241.
• 114 Liu J. et al. Pericardial adipose tissue, atherosclerosis, and cardiovascular disease risk factors: the Jackson heart study. Diabetes Care 2010; 33: 1635-1639.
• 115 Chaston TB, Dixon JB. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. Int J Obes 2008; 32: 619-628.
• 116 Snel M. et al. Effects of adding exercise to a 16-week very low-calorie diet in obese, insulin-dependent type 2 diabetes mellitus patients. J Clin Endocrinol Metabol 2012; 97: 2512-2520.
• 117 Thamer C. et al. High visceral fat mass and high liver fat are associated with resistance to lifestyle intervention. Obesity 2007; 15: 531-538.
• 118 Kim MK. et al. Comparison of epicardial, abdominal and regional fat compartments in response to weight loss. Nutr Metab Cardiovasc Dis 2009; 19: 760-766.
• 119 Snel M. et al. Long-term beneficial effect of a 16-week very low calorie diet on pericardial fat in obese type 2 diabetes mellitus patients. Obesity 2012; 20: 1572-1576.
• 120 Hammer S. et al. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol 2008; 52: 1006-1012.
• 121 Thomas EL. et al. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol 2006; 12: 5813-5819.
• 122 Viljanen AP. et al. Effect of weight loss on liver free fatty acid uptake and hepatic insulin resistance. J Clin Endocrinol Metab 2009; 94: 50-55.
• 123 Johnson NA. et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009; 50: 1105-1112.
• 124 Sullivan S. et al. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology 2012; 55: 1738-1745.
• 125 Kim MK. et al. Aerobic exercise training reduces epicardial fat in obese men. J Appl Physiol 2009; 106: 5-11.
• 126 Benraouane F, Litwin SE. Reductions in cardiovascular risk after bariatric surgery. Curr Opin Cardiol 2011; 26: 555-561.
• 127 Sjostrom L. et al. Bariatric surgery and long-term cardiovascular events. J Am Med Assoc 2012; 307: 56-65.
• 128 Chaston TB, Dixon JB. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. Int J Obes 2008; 32: 619-628.
• 129 Camastra S. et al. Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. Diabetologia 2011; 54: 2093-2102.
• 130 Poirier P. et al. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation 2011; 123: 1683-1701.
• 131 Buchwald H. et al. Bariatric surgery: a systematic review and meta-analysis. J Am Med Assoc 2004; 292: 1724-1737.
• 132 Heneghan HM. et al. Effect of bariatric surgery on cardiovascular risk profile. Am J Cardiol 2011; 108: 1499-1507.
• 133 Bradley D. et al. Effects of bariatric surgery on glucose homeostasis and type 2 diabetes. Gastroenterology 2012; 143 (04) 897-912.
• 134 Gaborit B. et al. Effects of Bariatric Surgery on Cardiac Ectopic Fat: Lesser Decrease in Epicardial Fat Compared to Visceral Fat Loss and No Change in Myocardial Triglyceride Content. J Am Coll Cardiol 2012; 60: 1381-1389.
• 135 Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic Fatty liver disease: a future treatment by choice or by chance?. J Obesity 2013; 2013: 839275.
• 136 Gastaldelli A. et al. The effect of pioglitazone on the liver: role of adiponectin. Diabetes Care 2006; 29: 2275-2281.
• 137 Cariou B. et al. Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol Metab 2012; 23: 205-215.
• 138 Defronzo RA. et al. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. Hosp Pract 2013; 41: 132-147.
• 139 Yau H. et al. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep 2013; 13: 329-341.
• 140 Vilsboll T. et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Br Med J 2012; 344: d7771.
• 141 Svegliati-Baroni G. et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 2011; 31: 1285-1297.
• 142 Simsek S, de Galan BE. Cardiovascular protective properties of incretin-based therapies in type 2 diabetes. Curr Opin Lipidol 2012; 23: 540-547.